更年期激素治疗规范管理的有效性及安全性评价

doi:10.3969/j.issn.1006-7795.2013.04.007

摘要/Abstract

摘要：

目的观察更年期女性激素治疗规范化管理的有效性、安全性,为临床规范化激素治疗提供理论依据。方法前瞻性研究分析2005年至2013年在首都医科大学附属北京妇产医院门诊就诊的更年期妇女,按患者意愿分为激素治疗组及对照组,随访时间5年,最后符合条件的激素治疗组20例,对照组16例。激素治疗组给予健康指导加个体化激素治疗,对照组给予健康指导。分析2组患者Kupperman评分、体质量指数(body mass index,BMI)、每公斤体质量静息能量消耗(resting energy expenditure,REE/kg)、全身脂肪含量(body fat percent,BF%)、血脂、肝功能、肾功能、乳腺腺体等随观察时间的变化,评估激素治疗的有效性及安全性。结果 1 激素治疗组Kupperman评分呈降低趋势(P>0.05)。2 激素治疗组及对照组BMI治疗期间差异无统计学意义(P>0.05);对照组BF%在观察第2年明显升高(P<0.05),而激素治疗组BF%在治疗第4年比第3年减少(P<0.05);对照组REE/kg在第2年明显降低(P<0.05),而激素治疗组REE/kg呈升高趋势(P>0.05)。3 对照组总胆固醇(TC)、三酰甘油(TG)呈升高趋势,低密度脂蛋白胆固醇(LDL-C)第5年与第4年相比明显升高(P<0.05),而激素治疗组TC、TG及LDL呈降低趋势,但差异无统计学意义(P>0.05),高密度脂蛋白胆固醇(HDL-C)治疗期间差异无统计学意义。4 激素治疗组肝肾功能在治疗期间变化差异无统计学意义。激素治疗起始与治疗第5年相比,乳腺腺体变化差异无统计学意义(P>0.05)。结论激素补充治疗可有效缓解更年期症状;可在一定程度上缓解绝经女性血脂的异常改变,同时可通过增加静息能量消耗,缓解更年期妇女全身脂肪含量逐年增加的趋势,进而缓解绝经后腹型肥胖的进展,在一定程度上可降低心血管疾病风险;规范化、个体化激素治疗乳腺癌风险小。

关键词: 更年期, 激素治疗, 有效性, 安全性

Abstract:

Objective To evaluate efficacy and safety of standardized management of hormone therapy in menopausal women. Methods The menopausal women visited the endocrine clinic of Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University after 2003 were divided into two group, hormone therapy and control group. There were 55 cases in hormone therapy group, and 34 cases in control group. We analyzed the variation of Kupperman sore, serum lipoprotein, resting energy expenditure, body fat, liver and renal function and mammary glands in the hormone therapy, so that assess the effectiveness and safety of hormone replacement therapy. Results 1 The Kupperman scores tended to decrease. 2 BMI did not change significantly in HT group and control group(P>0.05); BF% in the control group was significantly higher in the second year than the first year(P<0.05), while, compared with the first three years, the hormone therapy group BF% in the fourth year of treatment decreased significantly(P<0.05). Compared with the first year, REE/kg was reduced gradually in the second year in control group, however, REE/kg increased in HT group. 3 TC in control group increased gradually; LDL increased significantly in the second year(P<0.05). However, TC, TG and LDL-C were became lower gradually in HT group. 4 Liver and renal function was not significantly different during HT. The glands group of mammary gland between the first year and 5th year was not significantly different. Conclusion Hormone replacement therapy can relieve menopause-related symptoms; hormone therapy may alleviate abnormal blood lipids change in menopausal women; at the same time, it increases REE, eases the trend of BF% increase in menopausal women, so alleviates the progress of abdominal obesity after menopause, and to certain extent, it can reduce the risk of cardiovascular disease. During the standardized and individualized hormone therapy, the breast cancer risk is small.

Key words: menopause, hormone therapy, efficacy, safety

中图分类号:

R749.4⁺2

张俊丽, 阮祥燕, 刘玉兰, 甄洁, 殷冬梅, 王娟, 柳顺玉. 更年期激素治疗规范管理的有效性及安全性评价[J]. 首都医科大学学报, 2013, 34(4): 512-518.

ZHANG Junli, RUAN Xiangyan, LIU Yulan, ZHEN Jie, YIN Dongmei, WANG Juan, LIU Shunyu. Efficacy and safety evaluation of standardized management of hormone therapy in menopausal women[J]. Journal of Capital Medical University, 2013, 34(4): 512-518.

参考文献

[1] Grady D, Applegate W, Bush T, et al. Heart and Estrogen/progestin Replacement Study(HERS): design, methods, and baseline characteristics[J]. Control Clin Trials, 1998,19(4):314-335.

[2] Fischer J. Nutrition and life style prevent myocardial infarct and stroke: 14 years follow-up of the US-American Nurses Health Study[J]. Praxis(Bem 1994), 2001,90(7):271-272.

[3] Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study[J]. Lancet, 2003,362(9382):419-427.

[4] Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up(HERS II)[J]. JAMA, 2002,288(1):49-57.

[5] Amuna P, Zotor F B. Epidemiological and nutrition transition in developing countries: impact on human health and development[J]. Proc Nutr Soc, 2008,67(1):82-90.

[6] Wu Z, Yao C, Zhao D. Sino-MONICA project: a collaborativestudy on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring[J]. Circulation, 2001,103 (3):462-468.

[7] Pearson T A. New tools for coronary risk assessment: what are their advantages and limitations[J]. Circulation, 2002,105(7):886-892.

[8] Yang Z J, Liu J, Ge J P, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study[J]. Eur Heart J, 2012,33(2):213-220.

[9] 任晓红,孙英贤,李晓东,等.性急性心肌梗死患者临床及冠脉造影特点分析[J].中国医科大学学报,2010,39(4):298-300.

[10] He L,Tang X, Li N, et al. Menopause with cardiovascular disease and its risk factors: among rural Chinese women in Beijing: a population-based study[J]. Maturitas, 2012,72(2):132-138.

[11] Matthews K A, Crawford S L, Chae C U, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?[J]. J Am Coll Cardiol, 2009,54(25):2366-2373.

[12] Lamon-Fava S, Herrington D M, Horvath K V, et al. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status[J]. Metabolism, 2010,59(12):1794-1800.

[13] British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice[J]. Heart, 2005,91(Suppl 5):v1-v52.

[14] Kwok S, Canoy D, Soran H, et al. Body fat distribution in relation to smoking and exogenous hormones in British women[J]. Clin Endocrinol(Oxf), 2012,77(6):828-833.

[15] McTigue K, Larson J C, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women[J]. JAMA, 2006,296(1):79-86.

[16] Adams K F, Schatzkin A, Harris T B, et al.Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old[J]. N Engl J Med, 2006,355(8):763-778.

[17] Flegal K M, Graubard B I, Williamson D F, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity[J]. JAMA, 2007,298(17):2028-2037.

[18] Kwok S, Canoy D, Soran H, et al. Body fat distribution in relation to smoking and exogenous hormones in British women[J]. Clin Endocrinol(Oxf), 2012,77(6):828-833.

[19] Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913[J]. Br Med J(Clin Res Ed), 1984,288(6428):1401-1404.

[20] Seeger H, Mueck A O. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data[J]. J Steroid Biochem Mol Biol, 2008,109(1-2):11-15.

[21] Margolis K L, Bonds D E, Rodabough R J, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial[J]. Diabetologia, 2004,47(7):1175-1187.

[22] Stefanick M L, Anderson G L, Margolis K L, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy[J]. JAMA, 2006,295(14):1647-1657.

[23] de Villiers T J, Gass M L, Haines C J, et al. Global Consensus Statement on menopausal hormone therapy[J]. Maturitas, 2013,74(4):391-392.

[24] Mueck A O, Seeger H. The World Health Organization defines hormone replacement therapy as carcinogenic-is this plausible?[J]. Gynecol Endocrinol, 2008,24(3):129-132.

[25] 马骏,傅继华.生活方式与乳腺癌发病相关性的研究进展[J].中华肿瘤防治杂志,2012,19(5):397-400.

[26] Aguilar Cordero MJ, Neri Sánchez M, Padilla López CA, et al. Overweight/obesity in women and its implication in breast cancer: age of diagnosis[J]. Nutr Hosp, 2012,27(5):1643-1647.

[27] Hulka B, Moorman P G. Breast cancer: hormones and other risk factors[J]. Maturitas, 2008,61(1-2):203-213.

[28] Cummings S R, Tice J A, Bauer S. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk[J]. J Natl Cancer Inst, 2009,101(6):384-398.